Exact Sciences (EXAS) a One Trick Pony But Can Still Turn Heads
Tweet Send to a FriendGet Alerts EXAS Hot Sheet
Up)
Trade EXAS Now!
Shares of Exact Sciences (Nasdaq: EXAS) moved higher today after the company was featured in a weekend report by Barron’s. The company is developing a test that can detect colon cancers with more accuracy than screenings that are currently in use. If the test is eventually approved by the FDA, Exact Sciences could be acquired for upward of $20 per share, Barron's said.
Shares of Exact Sciences last traded at $11.92, up 2.5 percent from Friday's close.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
Shares of Exact Sciences last traded at $11.92, up 2.5 percent from Friday's close.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- Exact Sciences (EXAS) Prices 5.5M Shares at $12.35/Sh
- Streetinsider.com After-Hours Movers 06/17: (RMBS) (KFY) (IR) Higher; (GNMK) (SFL) (RPRX) Lower (more...)
- StreetInsider.com Pre-Open Movers 6/18: (WLT) (SNE) (RMBS) Higher; (SFL) (HRL) (GNMK) Lower (more...)
Create E-mail Alert Related Categories
Insiders' BlogRelated Entities
Barron's
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
